Fisheries & Fish Industry

Pharmaq opens high-tech viral antigen production facility in Norway

Pharmaq opens high-tech viral antigen production facility in Norway

On 1 November 2017, the Norwegian Medicines Agency granted Pharmaq authorisation to produce viral antigens at their new facility in Kløfta. The site has the capacity to produce several hundred million vaccine doses per annum to be used in Pharmaq’s fish vaccines and will ensure that they have the delivery capacity for the international aquaculture industry for many years to come.

Clint Lewis - Executive Vice President and President, International Operations, ZoetisClint Lewis – Executive Vice President and President, International Operations, Zoetis

Source: Pharmaq opens high-tech viral antigen production facility in Norway